Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis

Blood Transfusion

Volumn 12, Issue SUPPL.1, 2014, Pages

  Sundic, Tatjana ^a   Hervig, Tor ^b,c   Hannisdal, Signe ^b   Assmus, Jörg ^b   Ulvik, Rune J ^b,c   Olaussen, Richard W ^d   Berentsen, Sigbjorn ^a  

^a HAUGESUND HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Erythrocytapheresis; Erythrocyte apheresis; Haemochromatosis; Phlebotomy; Therapy.

Indexed keywords

FERRITIN; HEMOGLOBIN; TRANSFERRIN;

ADULT; AGED; APHERESIS; ARTICLE; COMPARATIVE STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OXYGEN SATURATION; PHLEBOTOMY; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL MARKERS; CYTAPHERESIS; FEMALE; FERRITINS; GENOTYPE; HEMOCHROMATOSIS; HEMOGLOBINS; HUMANS; IRON; MALE; MEDICAL LABORATORY PERSONNEL; MIDDLE AGED; NORWAY; PHLEBOTOMY; PROSPECTIVE STUDIES; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893902629     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0128-13     Document Type: Article

References (23)

1. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36: 1108-15.
2. Adams PC, Barton JC. Haemochromatosis. Lancet 2007; 370: 1855-60.
3. Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis: current concepts and progress. Am J Med 2006; 119: 391-9.
4. Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-78.
5. Brittenham GM. Disorders of iron metabolism: Iron deficiency and iron overload. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Silberstein LE, McGlave P et al., eds. Hematology: Basic Principles and Practice. Philadelphia: Churchill Livingstone Elsevier 2008: 453-68.
6. Adams PC, Barton JC. How I treat hemochromatosis. Blood 2010; 116: 317-25.
7. Asberg A, Hveem K, Kruger O, et al. Persons with screeningdetected haemochromatosis: as healthy as the general population? Scand J Gastroenterol 2002; 37: 719-24.
8. Ulvik RJ. Screening for haemochromatosis. Scand J Clin Lab Invest Suppl 1990; 202: 90-3.
9. Adams PC. Haemochromatosis: find them or forget about them? Eur J Gastroenterol Hepatol 2004; 16: 857-8.
10. Zoller WG, Kellner H, Spengel FA. Erythrocytapheresis. A method for rapid extracorporeal elimination of erythrocytes. Results in 65 patients. Klin Wochenschr 1988; 66: 404-9.
11. Muncunill J, Vaquer P, Galmes A, et al. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy. J Clin Apheresis 2002; 17: 88-92.
12. Hicken BL, Tucker DC, Barton JC. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis. Am J Gastroenterol 2003; 98: 2072-7.
13. Conte D, Mandelli C, Cesana M, et al. Effectiveness of erythrocytapheresis in idiopathic hemochromatosis. Report of 14 cases. Int J Artif Organs 1989; 12: 59-62.
14. Kellner H, Zoller WG. Repeated isovolemic largevolume erythrocytapheresis in the treatment of idiopathic hemochromatosis. Z Gastroenterol. 1992; 30: 779-83.
15. Kohan A, Niborski R, Daruich J, et al. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2000; 79: 40-5.
16. Mariani R, Pelucchi S, Perseghin P, et al. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage. Haematologica 2005; 90: 717-8.
17. Rombout-Sestrienkova E, van Noord PA, van Deursen CT, et al. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - a pilot study. Transfus Apher Sci 2007; 36: 261-7.
18. Knutsen H, Hammerstrom J. Norwegian national guidelines for treatment of haemochromatosis. [In Norwegian]. Norwegian Society of Haematology, 2003. Available at: http:// legeforeningen.no/PageFiles/5783/Handlingsprogram%20 for%20Hemokromatose.pdf. Accessed on 9 June 2013.
19. Aguilar-Martinez P, Grandchamp B, Cunat S, et al. Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants. Haematologica 2011; 96: 507-14.
20. Altman DG. Comparing groups - continuous data. In: Altman DG, ed. Practical Statistics for Medical Research. Washington DC: Chapman & Hall/CRC; 1999: 179-228.
21. Brissot P, De Bels F. Management of hemochromatosis linked to HFE gene. [In French; English abstract]. Presse Med 2007; 36: 1295-300.
22. Hagve TA, Asberg A, Ulvik R, et al. Hemochromatosis- from an underdiagnosed curiosity to a common disease. [In Norwegian; English abstract]. Tidsskr Nor Laegeforen 2009; 129: 863-6.
23. Rombout-Sestrienkova E, Nieman FH, Essers BA, et al. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial. Transfusion 2012; 52: 470-7.